CDK4 and breast carcinoma: Three CDK4/6 inhibitors (abemaciclib, palbociclib and ribociclib) have shown clinical benefit in patients with advanced hormone receptor (HR)-positive/HER2-negative breast cancer when given in combination with endocrine therapy [60,61,62,63,64,65,66].